Patents by Inventor Anna Helgadottir
Anna Helgadottir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9617597Abstract: The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.Type: GrantFiled: February 21, 2008Date of Patent: April 11, 2017Assignee: deCode Genetics ehfInventors: Anna Helgadottir, Gudmar Thorleifsson, Andrei Manolescu
-
Publication number: 20140227693Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: ApplicationFiled: January 13, 2014Publication date: August 14, 2014Applicant: deCODE Genetics ehf.Inventors: Anna Helgadottir, Daniel Gudbjartsson
-
Patent number: 8637244Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: GrantFiled: December 5, 2007Date of Patent: January 28, 2014Assignee: deCODE Genetics ehf.Inventors: Anna Helgadottir, Daniel Gudbjartsson
-
Publication number: 20120208709Abstract: The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease, MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.Type: ApplicationFiled: April 19, 2012Publication date: August 16, 2012Applicant: deCODE Genetics ehf.Inventors: Andrei Manolescu, Anna Helgadottir, Gudmar Thorleifsson
-
Patent number: 8158362Abstract: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.Type: GrantFiled: November 9, 2005Date of Patent: April 17, 2012Assignee: deCODE Genetics ehf.Inventors: Anna Helgadottir, Hákon Hákonarson, Jeffrey R. Gulcher, Mark E. Gurney
-
Patent number: 7851486Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.Type: GrantFiled: April 22, 2004Date of Patent: December 14, 2010Assignee: deCODE Genetics ehf.Inventors: Anna Helgadottir, Mark Gurney, Jeffrey R. Gulcher, Hákon Hákonarson
-
Publication number: 20100216863Abstract: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.Type: ApplicationFiled: March 30, 2006Publication date: August 26, 2010Applicant: deCODE Genetics ehf.Inventors: Anna Helgadottir, Hákon Hákonarson, Jeffrey R. Gulcher, Mark E. Gurney
-
Publication number: 20100120045Abstract: The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods.Type: ApplicationFiled: April 30, 2008Publication date: May 13, 2010Applicant: DECODE GENETICS EHFInventors: Anna Helgadottir, Gudmar Thorleifsson
-
Publication number: 20100068705Abstract: The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associates with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.Type: ApplicationFiled: February 21, 2008Publication date: March 18, 2010Applicant: deCode Genetics ehfInventors: Anna Helgadottir, Gudmar Thorleifsson, Andrei Manolescu
-
Publication number: 20090325163Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: ApplicationFiled: December 5, 2007Publication date: December 31, 2009Applicant: deCODE Genetics ehfInventors: Anna Helgadottir, Daniel Gudbjartsson
-
Patent number: 7507531Abstract: Linkage of Myocardial Infarction (MI) to a locus on chromosome 13q12-13 is disclosed. In particular, the FLAP gene within this locus is shown by association analysis to be a susceptibility gene for MI and stroke. Pathway targeting for drug delivery and diagnosis applications in identifying those at risk of developing MI or stroke, in particular are described.Type: GrantFiled: April 22, 2004Date of Patent: March 24, 2009Assignee: deCODE Genetics chf.Inventor: Anna Helgadottir
-
Publication number: 20080293750Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.Type: ApplicationFiled: January 31, 2005Publication date: November 27, 2008Inventors: Anna Helgadottir, Hakon Hakonarson, Jeffrey R. Gulcher, Mark E. Gurney
-
Publication number: 20070280917Abstract: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.Type: ApplicationFiled: November 9, 2005Publication date: December 6, 2007Applicant: deCODE Genetics, Inc.Inventors: Anna Helgadottir, Hakon Hakonarson, Jeffrey Gulcher, Mark Gurney
-
Publication number: 20060019269Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.Type: ApplicationFiled: March 30, 2005Publication date: January 26, 2006Applicant: deCODE Genetics, Inc.Inventors: Anna Helgadottir, Hakon Hakonarson, Jeffrey Gulcher, Mark Gurney
-
Publication number: 20050282855Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.Type: ApplicationFiled: January 30, 2004Publication date: December 22, 2005Applicant: deCODE Genetics ehf.Inventors: Anna Helgadottir, Mark Gurney, Jeffrey Gulcher, Hakon Hakonarson
-
Publication number: 20050272051Abstract: Linkage of myocardial infarction (MI) with a locus on chromosome 12q23 is disclosed. In particular, the LTA4H gene within this locus is shown by association analysis to be a susceptibility gene for MI. Methods for preventing and/or treating the recurrence of MI, in particular are described.Type: ApplicationFiled: September 17, 2004Publication date: December 8, 2005Applicant: deCODE genetics ehf.Inventors: Anna Helgadottir, Mark Gurney, Hakon Hakonarson, Jeffrey Gulcher
-
Publication number: 20050113408Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.Type: ApplicationFiled: April 22, 2004Publication date: May 26, 2005Applicant: deCODE genetics ehf.Inventors: Anna Helgadottir, Mark Gurney, Jeffrey Gulcher, Hakon Hakonarson
-
Publication number: 20050112611Abstract: Linkage of Myocardial Infarction (MI) to a locus on chromosome 13q12-13 is disclosed. In particular, the FLAP gene within this locus is shown by association analysis to be a susceptibility gene for MI and stroke. Pathway targeting for drug delivery and diagnosis applications in identifying those at risk of developing MI or stroke, in particular are described.Type: ApplicationFiled: April 22, 2004Publication date: May 26, 2005Applicant: deCODE genetics ehf.Inventor: Anna Helgadottir